Intravenous Acetaminophen in Craniotomy
Primary Purpose
Postoperative Pain
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Acetaminophen
Placebo
Sponsored by
About this trial
This is an interventional supportive care trial for Postoperative Pain focused on measuring Acetaminophen, Intravenous Acetaminophen, Opioid Requirement, Pain, Post-Operative Pain, Craniotomy, Post-Craniotomy Pain
Eligibility Criteria
Inclusion Criteria:
- Adults
- Undergoing Craniotomy for Supratentorial Tumor Resection
- Weight between 50 and 120 kilograms
- ASA Physical Status I-III
- Be able to communicate verbally
- Be able to use Visual Analog Score
Exclusion Criteria:
- Allergies to acetaminophen, morphine or any of the anesthetic agents required by the protocol.
- Use of opioids, tramadol, benzodiazepines, or gabapentin on a daily basis for > 7 days prior to the day of surgery.
- Use of acetaminophen, NSAIDs, or any other analgesic medication in the 12 hours immediately prior to study enrollment.
- Hepatic insufficiency (elevated transaminases > 1.5 times the upper limit of normal) or renal insufficiency (plasma creatinine > 2mg/dl).
- Known or suspected history of alcohol or illicit drug abuse.
- Pregnant or breast-feeding.
- Surgical plan for infratentorial (suboccipital) craniotomy.
- Plan for neurophysiologic monitoring that precludes the use of neuromuscular blockade.
- Inability to communicate due to a language barrier, impaired consciousness, cognitive defect or intellectual disability.
- Uncontrolled Hypertension
Sites / Locations
- Memorial Hermann Hospital - Texas Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Intravenous Acetaminophen
Placebo
Arm Description
Patients will be receive doses of 1000 mg/100 mL of IV Acetaminophen (OFIRMEV). The drug will be infused over 15 minutes.
Patients will be given 100 mL normal saline placebos at scheduled time intervals in place of IV acetaminophen.
Outcomes
Primary Outcome Measures
Post-Operative Opioid Requirement
Opioid Consumption will be monitored in the first 24 post-operative hours. All non-opioid analgesics are disallowed. Total opioid consumption was calculated based on morphine equivalents (MEs), where 1 mg of IV morphine was equivalent to 1 ME, and 1 mg IV hydromorphone was calculated as 7 MEs.
Secondary Outcome Measures
Post-Operative Pain
Patients will be assessed for pain using a Visual Analogue Scale (VAS) Scale at set time points after surgery (0,1,2,4,8,12,16,20,24 hours post-operatively). The Visual Analogue Scale (VAS) scale was measured on a scale of 0 - 10 (0 = no pain, 1-3 = mild, 4-6 = moderate, 7-10 = severe). Higher values on the VAS represent a worse outcome. The two rows below report: 1. the average VAS score for the least amount of pain reported per group and 2. the average VAS score of the worst amount of pain reported per group.
Post-Operative Side Effects
Patients will be monitored for 24 hours post-operatively to detect the incidence of any drug or opioid-related side effects. These side effects were not considered to be adverse events.
Time to Extubation at Emergence From Anesthesia
Time for Patient to Meet Post-anesthesia Care Unit (PACU) Discharge Criteria
Full Information
NCT ID
NCT01598701
First Posted
May 9, 2012
Last Updated
May 21, 2018
Sponsor
The University of Texas Health Science Center, Houston
Collaborators
Mallinckrodt
1. Study Identification
Unique Protocol Identification Number
NCT01598701
Brief Title
Intravenous Acetaminophen in Craniotomy
Official Title
The Opioid-Sparing and Analgesic Effects of IV Acetaminophen in Craniotomy: A Prospective, Randomized, Placebo-Controlled, Double-Blind Study
Study Type
Interventional
2. Study Status
Record Verification Date
May 2018
Overall Recruitment Status
Completed
Study Start Date
May 2, 2012 (Actual)
Primary Completion Date
March 30, 2016 (Actual)
Study Completion Date
March 30, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The University of Texas Health Science Center, Houston
Collaborators
Mallinckrodt
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to assess the use of intravenous Acetaminophen (OFIRMEV) as an effective adjunct therapeutic agent in patients undergoing craniotomy.
Detailed Description
General anesthesia will be induced by bolus administration of propofol (1.5-2.5 mg/kg IV), and fentanyl (2-3 µg/kg IV). Neuromuscular blockade will be achieved with bolus administration of rocuronium, vecuronium, or succinylcholine. Once the endotracheal tube is secured in place, the patient will be mechanically ventilated to an end-tidal CO2 of 35 mmHg. Additional procedures will include radial arterial line placement for invasive arterial blood pressure monitoring, as well as additional large-bore peripheral IV placements, or central line placement, if indicated. Anesthesia will be maintained with desflurane, propofol, and remifentanil.
Once general anesthesia has been induced, but prior to the first surgical incision, the first dose of the interventional agent will be administered. Repeat doses will be administered every 6 hours until 24 hours from the time that the patient enters the PACU, for a total of up to 6 doses. Once the patient has been positioned and prepped for surgery, the surgeon will infiltrate the scalp with bupivacaine 0.5% with epinephrine 1:200,000 (15-20 ml) before skin incision.
No other opioids or agents with analgesic properties (e.g., ketorolac, dexmedetomidine, ketamine) will be administered at any time during the operation. Additional medications that will be routinely administered for this procedure include dexamethasone 8-12mg IV prior to incision, and ondansetron 4mg IV at skin closure. Anticonvulsant drugs will be administered at the surgeon's request.
Emergence and extubation will occur at the completion of the case per standard guidelines. The time of remifentanil infusion discontinuation and time of extubation will be noted. If necessary, extubation may occur in the post anesthesia recovery unit (PACU); otherwise, extubation will occur in the operating room.
The patient will then be taken directly to the PACU. Inability to extubate a patient within two hours of completion of surgery will result in their withdrawal from the study. Once in the PACU, immediate postoperative vital signs will be recorded, including blood pressure, heart rate, respiratory rate, oxygen saturation, and RASS score.
Pain scores will be assessed using the visual analog scale (VAS) upon entering the PACU or upon extubation in PACU (0 hours), and then again at 1, 2, 4, 8, 12, 16, 20, and 24 hours post-operatively. The VAS will be a 10 cm scale on a numerical scale of 0 (no pain) to 10 (severe pain) that the patient will point to in order to indicate their current level of pain. Pain scores will be measured while the patient is at rest. Post-operative nausea will also be recorded on a 10 cm numeric rating scale (NRS) at the same time intervals, with 0 indicating no nausea and 10 indicating severe nausea. All day-time VAS and NRS measurements will be made by a research assistant. Night-time measurements will be made by the nurse on the unit.
While in the PACU, the time until the patient receives their first dose of analgesic medicine will be recorded. Patients will be given a 2mg nurse-administered dose of morphine upon request or if they report a pain score of ≥4/10, and will continue to be given morphine doses based on clinical assessment by the PACU/intensive care nurse, who will be blind to patient group allocation. The nurse will objectively assess the patient's pain score at least once an hour using the VAS pain scale, and an assessment of pain ≥4/10 will warrant an additional 2mg dose of morphine. Morphine dosage requirements will be recorded for 24 hours post-operatively. If morphine requirement is greater than 10mg in a 30 minute period or the patient develops an allergic reaction, pruritus, renal insufficiency, drowsiness, nausea/vomiting, or clinically relevant reason to change medication, the PACU supervising physician or ICU physician may use their clinical discretion to change the opioid rescue medication to hydromorphone (0.3mg doses). The reason for changing medication will be reported by the physician and recorded. The morphine equivalent of hydromorphone will be estimated to be 7 times the hydromorphone dose. The PACU/ICU nurses will also record any episodes of emesis, use of rescue anti-emetic medicine, and the occurrence of any other side effects.
A post-operative neurologic examination will take place in the PACU. Criteria for a neurological exam to be complete is the patient's ability to successfully lift each leg off of the bed for more than two seconds on command, and to be able to hold up two fingers on each hand on command. If these criteria are not met prior to transferring the patient from the PACU to the ICU, a post-operative neurologic complication will be considered and the patient will be withdrawn from the study.
The time until the patient is ready to be discharged from the PACU will also be noted. Patients with a modified Aldrete score of ≥ 8 (see Appendix 1) will be considered ready for discharge. These criteria will be assessed by either the research assistant or PACU staff.
At the end of the 24 hour post-operative time period, a patient interview will be conducted. At this interview the patient will asked about their subjective satisfaction with their analgesic protocol, as well as any adverse effects they may have noticed. The 24 hour morphine consumption will also be recorded at this time.
After the study is completed, patients may receive IV or oral acetaminophen therapy at the discretion of the primary physician.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Pain
Keywords
Acetaminophen, Intravenous Acetaminophen, Opioid Requirement, Pain, Post-Operative Pain, Craniotomy, Post-Craniotomy Pain
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
100 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Intravenous Acetaminophen
Arm Type
Experimental
Arm Description
Patients will be receive doses of 1000 mg/100 mL of IV Acetaminophen (OFIRMEV). The drug will be infused over 15 minutes.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Patients will be given 100 mL normal saline placebos at scheduled time intervals in place of IV acetaminophen.
Intervention Type
Drug
Intervention Name(s)
Acetaminophen
Other Intervention Name(s)
OFIRMEV
Intervention Description
Intravenous Acetaminophen, 1000 mg/100mL, Every 6 hours, Infused over 15 minutes.
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
0.9% Sodium Chloride
Intervention Description
100 mL 0.9% Sodium Chloride
Primary Outcome Measure Information:
Title
Post-Operative Opioid Requirement
Description
Opioid Consumption will be monitored in the first 24 post-operative hours. All non-opioid analgesics are disallowed. Total opioid consumption was calculated based on morphine equivalents (MEs), where 1 mg of IV morphine was equivalent to 1 ME, and 1 mg IV hydromorphone was calculated as 7 MEs.
Time Frame
24 hours post-operatively
Secondary Outcome Measure Information:
Title
Post-Operative Pain
Description
Patients will be assessed for pain using a Visual Analogue Scale (VAS) Scale at set time points after surgery (0,1,2,4,8,12,16,20,24 hours post-operatively). The Visual Analogue Scale (VAS) scale was measured on a scale of 0 - 10 (0 = no pain, 1-3 = mild, 4-6 = moderate, 7-10 = severe). Higher values on the VAS represent a worse outcome. The two rows below report: 1. the average VAS score for the least amount of pain reported per group and 2. the average VAS score of the worst amount of pain reported per group.
Time Frame
24 Hours Post-Operatively
Title
Post-Operative Side Effects
Description
Patients will be monitored for 24 hours post-operatively to detect the incidence of any drug or opioid-related side effects. These side effects were not considered to be adverse events.
Time Frame
24 Hours Post-Operatively
Title
Time to Extubation at Emergence From Anesthesia
Time Frame
Time from of discontinuation of anesthetic to time of extubation, an average of 7 minutes
Title
Time for Patient to Meet Post-anesthesia Care Unit (PACU) Discharge Criteria
Time Frame
From time of entry to PACU to time to meet PACU discharge criteria, an average of 12 minutes
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
120 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adults
Undergoing Craniotomy for Supratentorial Tumor Resection
Weight between 50 and 120 kilograms
ASA Physical Status I-III
Be able to communicate verbally
Be able to use Visual Analog Score
Exclusion Criteria:
Allergies to acetaminophen, morphine or any of the anesthetic agents required by the protocol.
Use of opioids, tramadol, benzodiazepines, or gabapentin on a daily basis for > 7 days prior to the day of surgery.
Use of acetaminophen, NSAIDs, or any other analgesic medication in the 12 hours immediately prior to study enrollment.
Hepatic insufficiency (elevated transaminases > 1.5 times the upper limit of normal) or renal insufficiency (plasma creatinine > 2mg/dl).
Known or suspected history of alcohol or illicit drug abuse.
Pregnant or breast-feeding.
Surgical plan for infratentorial (suboccipital) craniotomy.
Plan for neurophysiologic monitoring that precludes the use of neuromuscular blockade.
Inability to communicate due to a language barrier, impaired consciousness, cognitive defect or intellectual disability.
Uncontrolled Hypertension
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Carlos A. Artime, MD
Organizational Affiliation
University of Texas Health Sciences Center at Houston
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sam D. Gumbert, MD
Organizational Affiliation
University of Texas Health Sciences Center at Houston
Official's Role
Principal Investigator
Facility Information:
Facility Name
Memorial Hermann Hospital - Texas Medical Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
29117012
Citation
Artime CA, Aijazi H, Zhang H, Syed T, Cai C, Gumbert SD, Ferrario L, Normand KC, Williams GW, Hagberg CA. Scheduled Intravenous Acetaminophen Improves Patient Satisfaction With Postcraniotomy Pain Management: A Prospective, Randomized, Placebo-controlled, Double-blind Study. J Neurosurg Anesthesiol. 2018 Jul;30(3):231-236. doi: 10.1097/ANA.0000000000000461.
Results Reference
result
Learn more about this trial
Intravenous Acetaminophen in Craniotomy
We'll reach out to this number within 24 hrs